Guangdong QiFang Medicine Co. Ltd.

Primary objective: To evaluate the safety and tolerability of multiple doses of hepnofovir fumarate in the treatment of patients with chronic hepatitis B, and to compare the safety and tolerability with that of tenofovir alafenamide fumarate. Secondary objectives: 1. To evaluate the pharmacokinetic characteristics of hepnofovir fumarate in patients with chronic hepatitis B after continuous oral administration of hepnofovir fumarate to steady state; 2. To evaluate the pharmacodynamic changes after multiple doses of hepnofovir fumarate, mainly including the changes in serum HBV DNA and serum markers (HBsAg, HBeAg, HBeAb) compared with the baseline period, and to compare the efficacy with that of the tenofovir alafenamide fumarate group.

To study the pharmacokinetic characteristics of CE-fosphenytoin sodium injection (T), fosphenytoin sodium injection (R1) and phenytoin sodium injection (R2) administered by intravenous infusion, and to evaluate the bioequivalence of the three preparations; To study the pharmacokinetic characteristics of CE-fosphenytoin sodium injection (T) and fosphenytoin sodium injection (R1) administered by intramuscular injection, and to evaluate the bioequivalence of the two preparations. To evaluate the safety of CE-fosphenytoin sodium injection (T), fosphenytoin sodium injection (R1) and phenytoin sodium injection (R2) in healthy subjects.

To evaluate the tolerability of multiple-dose, single-dose and multiple-dose hepnofovir fumarate tablets in healthy subjects; To evaluate the pharmacokinetics of multiple-dose, single-dose and multiple-dose hepnofovir fumarate tablets in healthy subjects; To preliminarily explore the drug metabolism transformation of hepnofovir fumarate tablets; To evaluate the effect of food on the pharmacokinetics of hepnofovir fumarate.